(AMEX:VNRX) is preparing to announce its quarterly earnings on April 1, 2026. Analysts predict an earnings per share (EPS) of -$0.04, with expected revenue of $753,575. VolitionRx is a multi-national epigenetics company focused on developing blood tests for cancer and other diseases, competing with other biotech firms in the diagnostic space.
Recently, VolitionRx secured €2 million (about $2.3 million) in non-dilutive funding from Belgian agencies Namur Invest and Wallonie Entreprendre S.A. This funding will aid the development of the Nu.Q product portfolio, including the regulatory transition of Nu.Q NETs from IVDD to IVDR. It will also support research for a Lateral Flow product to improve access in low-income countries.
The company has also published a clinical study in the Shock Journal, revealing elevated nucleosome levels in trauma patients using its Nu.Q biomarkers. This study, conducted with the Mayo Clinic, highlights the potential of these biomarkers in emergency and surgical settings, addressing an unmet need for reliable trauma patient indicators.
At the European Lung Cancer Conference, VolitionRx presented an abstract on using Nu.Q Cancer assays for lung cancer management. The study found that high levels of H3K27Me3-nucleosomes, measured preoperatively, could identify patients needing closer follow-ups or additional treatments, as these levels correlate with poorer survival outcomes.
In its recent financial report, VolitionRx recorded a quarterly revenue of $627,000 but faced a net loss of $5.4 million. Despite a gross profit of $627,000, the company reported a negative operating income of $5.1 million and a negative EBITDA of $4.2 million. The EPS for the quarter was a loss of $0.05, with an income before tax loss of $5.4 million.
